NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.280
+0.020 (1.59%)
Oct 2, 2026, 4:00 PM EDT - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,174,073
Market Cap
32.67M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| IGC Pharma | 70 |
| Seres Therapeutics | 66 |
| aTyr Pharma | 60 |
| BeyondSpring | 44 |
| Quince Therapeutics | 38 |
| Actinium Pharmaceuticals | 27 |
| Quantum BioPharma | 17 |
NNVC News
- 3 days ago - NanoViricides ‘actively exploring’ additional required funding - TheFly
- 3 days ago - NanoViricides reports FY26 EPS (41c) vs. (63c) last year - TheFly
- 3 days ago - NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - Accesswire
- 4 days ago - NanoViricides says Phase II trial of NV-387 in ebola starts enrollment, dosing - TheFly
- 4 days ago - Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides - Accesswire
- 9 days ago - NanoViricides begins Phase II trial of NV-387 in Monkeypox in DRC - TheFly
- 9 days ago - Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides - Accesswire
- 17 days ago - NanoViricides to begin Phase II trial of NV-387 in ebola next week - TheFly